We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Integrated Cervical Cancer Testing Provides Leading-Edge Solutions for New Screening Needs

By LabMedica International staff writers
Posted on 19 Nov 2013
An integrated set of assays and instruments used for cervical cancer testing enables laboratories and physicians to provide high diagnostic accuracy combined with screening efficiency for their patients.

Virtually all known cases of cervical cancer are caused by specific types of human papillomavirus (HPV), with 14 HPV genotypes being considered high-risk (HR) for causing cancer. BD Diagnostics, a segment of Becton, Dickinson and Company (BD; Franklin Lakes, NJ, USA), has announced at EUROGIN 2013 that BD has achieved CE/IVD marking of its “Totalys” MultiProcessor, an automated instrument that integrates the preprocessing for BD’s “SurePath” Liquid-based Pap Test with a molecular aliquot, maintaining sample integrity while improving laboratory efficiency. At the conference, BD also highlighted the performance of its new “Onclarity” HPV Assay on the BD “Viper” LT System, which is pending EU certification.

Image: BD’s Totalys MultiProcessor, an automated instrument that integrates the preprocessing for BD’s SurePath Liquid-based Pap Test with a molecular aliquot, maintaining sample integrity while improving laboratory efficiency (Photo courtesy of BD Diagnostics).
Image: BD’s Totalys MultiProcessor, an automated instrument that integrates the preprocessing for BD’s SurePath Liquid-based Pap Test with a molecular aliquot, maintaining sample integrity while improving laboratory efficiency (Photo courtesy of BD Diagnostics).

“These new products are part of BD’s integrated Women's Health portfolio and support full sample chain of custody, high diagnostic accuracy, and a clear patient management approach – all important elements to improving patient care,” said Paul Holt, Global Market Segment Leader, Women’s Health & Cancer, BD Diagnostics.

The Totalys MultiProcessor provides balance of automation and flexibility, streamlining processes and removing inefficiencies. The highly automated sample preparation for cytology and molecular testing helps enhance lab productivity, while random sample loading reduces hands-on time. The system provides remote diagnostic and service capabilities to maintain optimal system uptime.

The Onclarity HPV Assay targets E6/E7 DNA oncogenes and is designed to provide physicians access to broader HPV genotype information to guide informed treatment decisions. The assay reports results on six discrete high-risk HPV genotypes (16, 18, 45, 31, 51, and 52) with the remaining eight HR genotypes reported in three small groups: (33, 58), (35, 39, 68) and (56, 59, 66). HR genotype and genotype group results are obtained from the same sample with no additional processing steps. The Onclarity HPV Assay is designed for the BD Viper LT System, a bench-top instrument that automates sample setup, DNA extraction, RT PCR amplification and detection with minimal lab technician intervention during processing. The Viper LT System’s integrated design and ease-of-use supports adoption in both cytology and molecular laboratory environments. The BD Onclarity HPV Assay is pending EU certification and is expected to be available December 2013 in Europe and Asia (not currently for sale or distribution in the USA).

Related Links:

Becton, Dickinson and Company



New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Alcohol Testing Device
Dräger Alcotest 7000
New
Hemodynamic System Monitor
OptoMonitor

Latest Molecular Diagnostics News

New Blood Tests Could Catch Blood Cancer Earlier
19 Nov 2013  |   Molecular Diagnostics

ctDNA Testing Outperforms Traditional Imaging in Predicting Patients Outcomes in Large B-Cell Lymphoma
19 Nov 2013  |   Molecular Diagnostics

New Statistical Tool Reveals Hidden Genetic Pathways in Complex Diseases
19 Nov 2013  |   Molecular Diagnostics